Coverage, which is measured for women aged 53-70, dropped slightly to 74.6% in 2018-19, from 74.9% in 2017-18.
Coverage figures are based on the proportion of the eligible population screened within the last three years.
Therefore, coverage is affected by population fluctuations and screening activity over a three-year period - so changes in coverage may not directly mirror changes in the number of invites or screens in a given year. Uptake
Uptake of routine invitations for women aged 50 to 70 was 71.1% in 2018-19 (1.82m women), up from 70.5% in 2017-18 (1.79m).
The report shows that uptake was highest in the North East sub region at 75.3%.
Uptake was above the national minimum standard of 70% in all regions except London, where it was 64.0% and the North West, where it was 69.5%. Outcomes
In 2018-19, 84,559 women aged 45 and over were referred for assessment following screening. The total proportion of women aged 45 and over that were referred for assessment fell from 3.9% in 2017-18 to 3.8% in 2018-19. Cancer detection
In the core cohort of women aged 50-70, cancer detection remained broadly similar, with an increase in rate from 8.1 cases per 1,000 women screened in 2017-18, to 8.2 cases per 1,000 women screened in 2018-19.
In the wider cohort, the number of women aged 45 and over with cancers detected increased from 18,001 in 2017-18 to 19,558 in 2018-19. This is an increase in the rate of cancers detected from 8.4 cases per 1,000 women screened in 2017-18 to 8.8 cases per 1,000 women screened in 2018-19.
The greatest increases are in the 71 to 74 age range (13.4 cases per 1,000 women screened in 2017-18, to 14.1 cases per 1,000 women screened in 2018-19) and the 75 and over age range (17.4 cases per 1,000 women screened in 2017-18, to 18.8 cases per 1,000 women screened in 2018-19).
Under the NHS Breast Screening Programme, eligible women will usually receive their first routine invitation for breast cancer screening between the ages of 50 and 53 and will normally be invited every three years until they are 70. Source:
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology